title: Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
abstract: A comprehensive database inquiry at our institutions identified 11 patients with echocardiogram-documented idiopathic cardiomyopathy that post-dated a diagnosis of either polycythemia vera or essential thrombocythemia. Anagrelide therapy was temporally associated with the particular complication in 6 patients, all of whom experienced symptomatic and/or objective improvement after drug discontinuation.
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Jurgens
authors.forename: Alvaro
authors.initials: A
authors.lastname: Moreno-Aspitia
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D009202:Cardiomyopathies / Q000139:chemically induced*; D005260:Female; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide